Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (54)

I-01Noha Abdelgawad

Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis

Wednesday 10:00-11:30

I-07Mounier Almett

Population Pharmacokinetic Modelling of Twice Daily 50mg Dolutegravir in Children with Tuberculosis and HIV during Rifampicin Co-administration

Wednesday 10:00-11:30

I-10Arkadiusz Adamiszak

Antibiotic pharmacokinetic modelling versus antibiotic therapy optimisation and resistance reduction: Bibliometric analysis

Wednesday 10:00-11:30

I-13Aurélie Barrail-Tran

Population pharmacokinetic modelling of dolutegravir, tenofovir and emtricitabine in non-human primates

Wednesday 10:00-11:30

I-19Sandra Berja

Population PK analysis of chloroquine in a humanized mouse model of P.falciparum malaria

Wednesday 10:00-11:30

I-22Jose Miguel Calderin Miranda

Pharmacokinetic analysis of pyrazinamide in a South African population with tuberculosis meningitis and HIV

Wednesday 10:00-11:30

I-25Anan Chanruang

Population pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV and TB

Wednesday 10:00-11:30

I-26Zhendong Chen

Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in patients with external ventricular drain

Wednesday 10:00-11:30

I-32Ivan Demin

Population pharmacokinetics of LXE408 in healthy volunteers and dose predictions for adults and pediatric patients with visceral leishmaniasis

Wednesday 10:00-11:30

I-34Thomas Duflot

Modelling of plasma unbound Ceftriaxone: can we improve efficacy in clinical practice ?

Wednesday 10:00-11:30

I-39Aneeq Farooq

In vitro pharmacokinetic/pharmacodynamic interaction model assessing the synergy between meropenem and fosfomycin in a clinical multi-resistant K. pneumoniae isolate.

Wednesday 10:00-11:30

I-43Wei Gao

Population PK/PD modeling of blood- and liver-stage activities of cabamiquine in malaria

Wednesday 10:00-11:30

I-45Kamunkhwala Gausi

Bactericidal activity of pretomanid against drug-sensitive tuberculosis in the presence of rifamycins

Wednesday 10:00-11:30

I-54Ibtihel Hammami

Application of Physiologically Based Pharmacokinetic Model to Predict Cobicistat Concentration during Pregnancy

Wednesday 10:00-11:30

I-55Irene Hernández-Lozano

Translational pharmacokinetic-pharmacodynamic (PKPD) modelling of apramycin to facilitate prediction of efficacious dose in urinary tract infections

Wednesday 10:00-11:30

I-62Felix Jost

Model-based analysis of the treatment window in passive cutaneous anaphylaxis mouse model applying an optimized study design

Wednesday 10:00-11:30

I-63Piotr Juszczak

Modelling humoral immune response after a single RSV vaccination in RSV-seropositive adults aged 60 and older

Wednesday 10:00-11:30

I-64Allan Kengo

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.

Wednesday 10:00-11:30

I-65Charlotte Kern

Oral ivermectin population pharmacokinetics modeling in venous plasma in healthy study participants in Kenya in preparation of BOHEMIA cluster randomized controlled trial

Wednesday 10:00-11:30

I-66Dohoon Keum

Model-based optimal dosing regimen for recombinant hepatitis B human immunoglobulin (GC1102) in Chronic Hepatitis B Patients

Wednesday 10:00-11:30

I-69Simon Koele

Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis

Wednesday 10:00-11:30

I-72Yu-wei Lin

Population pharmacokinetic analysis of DOVATO (DTG/3TC) as a fixed-dose combination (FDC), in antiretroviral therapy (ART)-naive HIV-1-infected adolescents, ≥12 to <18 years of age who weigh at least 25 kg

Wednesday 10:00-11:30

I-92Sebastian Wicha

In vitro pharmacodynamic drug-drug interaction and translational evaluation of cabamiquine and pyronaridine as new antimalarial combination using P.falciparum field isolates

Wednesday 10:00-11:30

I-93Marie Wijk

Analysis of Mycobacterium tuberculosis time to positivity in response to treatment in South African patients with drug-susceptible tuberculosis

Wednesday 10:00-11:30

I-94Venkata Yellepeddi

Population Pharmacokinetics of Intermittent Vancomycin in Cystic Fibrosis Patients

Wednesday 10:00-11:30

I-97Yu-Jou Lin

A pharmacometric multistate model for analyzing long-term outcomes of patients with drug-resistant tuberculosis under bedaquiline treatment

Wednesday 10:00-11:30

IV-06Lu Chen

Posaconazole meta-PK analysis upon oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race

Thursday 15:25-16:55

IV-19Ryuji Kubota

Developing SARS-CoV-2 viral dynamic model in patients with COVID-19 based on amount of viral RNA and viral titer

Thursday 15:25-16:55

IV-21Minji Kwon

Optimization of dosing strategy for vancomycin using a population pharmacokinetic model combined with machine learning approaches

Thursday 15:25-16:55

IV-24Silvia Maria Lavezzi

Sensitivity analysis of a two-state bacterial model for prediction of clinical short-term bactericidal efficacy in tuberculosis: GSK3036656 case study

Thursday 15:25-16:55

IV-25Albin Leding

Population pharmacokinetics of the antitubercular drug TBAJ587 and its two main metabolites

Thursday 15:25-16:55

IV-28Giulia Lestini

Population pharmacokinetics of KAF156/LUM-SDF and exposure-response analysis for the probability of cure for patients with uncomplicated malaria

Thursday 15:25-16:55

IV-30Letao Li

Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: does inflammation play a role?

Thursday 15:25-16:55

IV-37Wen Yao Mak

Population pharmacokinetics and pharmacodynamics of eravacycline against pulmonary infections

Thursday 15:25-16:55

IV-41Laurynas Mockeliunas

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Thursday 15:25-16:55

IV-42Felix Müller

Identification and quantification of variability in the microdialysis technique using mixed-effects modelling within an integrated in vitro and ex vivo approach: a linezolid case study.

Thursday 15:25-16:55

IV-45Jacinta Nwogu

Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites

Thursday 15:25-16:55

IV-46Amaury O'Jeanson

Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) combinations: should we monitor the BLI concentration?

Thursday 15:25-16:55

IV-51Elena Pascual García

Towards model-informed design of antibiotic therapies: understanding the impact of antibiotics on bacterial physiology & growth.

Thursday 15:25-16:55

IV-54Anh Duc Pham

Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae and Pseudomonas aeruginosa

Thursday 15:25-16:55

IV-57Veshni Pillay-Fuentes Lorente

Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites

Thursday 15:25-16:55

IV-58Tim Preijers

Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 immunoglobulins: a phase I/II dose finding study

Thursday 15:25-16:55

IV-63Juan Eduardo Resendiz Galvan

Pharmacokinetics of cycloserine in an Indian population with multidrug-resistant tuberculosis.

Thursday 15:25-16:55

IV-70Louis Sandra

Development of an indirect response model-based meta-analysis (MBMA) framework for the description of viral antigen decline for siRNA-based anti-HBV therapies

Thursday 15:25-16:55

IV-72Maria Sanz Codina

Evaluating ceftazidime-avibactam exposure in patients undergoing automated peritoneal dialysis using population pharmacokinetic modelling

Thursday 15:25-16:55

IV-73Raphaël Saporta

Translation of the in vitro antimicrobial activity of afabicin against Staphylococcus aureus to in vivo bacterial killing dynamics using a pharmacokinetic-pharmacodynamic model based on time-kill experiments

Thursday 15:25-16:55

IV-75Sharon Sawe

Population pharmacokinetics of levofloxacin in South African adults treated for rifampicin-resistant tuberculosis.

Thursday 15:25-16:55

IV-77Manna Semere Gebreyesus

Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy

Thursday 15:25-16:55

IV-79Budi Octasari Susanto

Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations

Thursday 15:25-16:55

IV-84Marinda van de Kreeke

Interspecies scaling of host inflammatory response during infection

Thursday 15:25-16:55

IV-86Wisse van Os

Model-based comparison of antibiotic activity at target-site concentrations: a case study with ceftaroline and lefamulin for soft-tissue infections

Thursday 15:25-16:55

IV-88Peter Velickovic

Protocol optimization for the evaluation of pharmacokinetics, biomarkers and efficacy of antitubercular drugs in a novel tuberculosis infection model in marmosets

Thursday 15:25-16:55

IV-89Diego Vera-Yunca

A translational semi-mechanistic pharmacokinetic-pharmacodynamic framework to design animal studies: Application to linezolid and vancomycin

Thursday 15:25-16:55

IV-91Thanakorn Vongjarudech

Optimal longitudinal QT interval correction method considering changes in heart rate variability in patients treated for drug-resistant tuberculosis

Thursday 15:25-16:55